KRAS突变中包含靶向EGFR治疗的有效亚型,如KRASG13D。西妥昔单抗和帕尼单抗为代表的EGFR单抗在治疗RAS野生型mCRC上效果显著,但是大部分患者在治疗后期会逐渐产生继发性耐药,耐药的主要原因是RAS基因的继发性突变。此外,部分患者会在停药后耐药性逐渐降低。化...
Mutations in the potential predictive biomarkers BRAF and PIK3CA as well as protein expression of EGFR and PTEN were also determined.Four out of seven KRAS-mutated cell lines were characterised by the p.G13D mutation. Treatment of these cells using Cmab/Pmab induced a significant growth ...
KRAS是实体瘤中最常见的癌基因之一，大约七分之一的癌症患者携带KRAS突变基因，这包括约90%的胰腺癌，40%的结直肠癌和30%的非小细胞肺癌。KRAS突变包括诸多不同的位点突变，其中最常见的是G12C、G12D和G12R突变，除此之外，还有G12V、G13D、G12A或KRAS野生型扩增等。KRAS蛋白是一种小型膜结合GTP酶（GTP水解...
Gilbert J. Cote, Maria E. Cabanillas, and Marie-Claude Hofmann. 2016. “Long-Term Vemurafenib Treatment Drives Inhibitor Resistance through a Spontaneous KRAS G12D Mutation in a BRAF V600E Papillary Thyroid Carcinoma Model.” Oncotarget 7(21):30907–23. doi: 10.18632/oncotarget.9023.Evelyn...
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab CONTEXT: Patients with metastatic colorectal cancer who have KRAS codon 12- or KRAS codon 13-mutated tumors are presently excluded from treatment with the ... ...
其中最常见的是G12C、G12D和G12R突变，除此之外，还有G12V、G13D、G12A或KRAS野生型扩增等。
Vaccination allows the KRAS-mutant tumor antigen to cause T cell responses, which has become a promising treatment. Both the T cell pools of healthy individuals and cancer patients contain T cells that can identify KRAS mutation. After vaccination those T cells can be selectively expanded in ...
Molecular biomarkers to determine the effectiveness of targeted therapies in cancer treatment have been widely adopted in colorectal cancer (CRC), but those to predict chemotherapy sensitivity remain poorly defined. We tested our hypothesis that KRAS mutation may be a predictor of oxaliplatin sensitivity...
任何具有 KRAS G12D 或 G13D 突变的实体瘤。 BCA101 和派姆单抗组合的实验组对象包括: 头颈部鳞癌(HNSCC) 肛管鳞状细胞癌(SCCAC) 通过结合 KRAS 的直接抑制剂和下游抑制剂,该领域正在进入一个激动人心的创新临床试验时代,这些试验有可能改善这种突变患者的预后并提高其生存率。
英文名称:KRAS G13D peptide,25 mer 用途:科研 纯度:98% CAS编号:145019-94-9 品牌:Chemstan 包装规格:100 mg 货号:CS-P3129 是否进口:否 Description KRAS G13D peptide,25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D...